Source: Annual Congress 2012 - Asthma: mechanisms of airway inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wegmann, L. Lunding, Z. Orinska, D.M. Wong, R.A. Manz, H. Fehrenbach (Borstel, Germany). Long-term bortezomib treatment decreases allergen-specific IgE but fails to amend chronic asthma in mice. Eur Respir J 2012; 40: Suppl. 56, 2370

Member's Comments

No comment yet.

Related content which might interest you: Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Relationship between pre-treatment specific IgE and the response to omalizumab therapy Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Returning asthma symptoms correlate with free IgE upon omalizumab cessation Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Anti-IgE treatment in children with severe intrinsic asthma Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019